Literature DB >> 28473066

ACR Appropriateness Criteria® Chronic Liver Disease.

Jeanne M Horowitz1, Ihab R Kamel2, Hina Arif-Tiwari3, Sumeet K Asrani4, Nicole M Hindman5, Harmeet Kaur6, Michelle M McNamara7, Richard B Noto8, Aliya Qayyum6, Tasneem Lalani9.   

Abstract

Because liver fibrosis can be treated, it is important to diagnose liver fibrosis noninvasively and monitor response to treatment. Although ultrasound (grayscale and Doppler) can diagnose cirrhosis, it does so unreliably using morphologic and sonographic features and cannot diagnose the earlier, treatable stages of hepatic fibrosis. Transient elastography, ultrasound elastography with acoustic radiation force impulse, and MR elastography are modalities that can assess for hepatic fibrosis. Although all international organizations recommend ultrasound for screening for hepatocellular carcinoma, ultrasound is particularly limited for identifying hepatocellular carcinoma in patients with obesity, nonalcoholic fatty liver disease, and nodular cirrhotic livers. In these patients, as well as patients who are on the liver transplant wait list, ultrasound is so limited that consideration can be made for screening for hepatocellular carcinoma with either MRI or multiphase CT. Additionally, patients who have been previously diagnosed with and treated for hepatocellular carcinoma require continued surveillance for recurrent hepatocellular carcinoma. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Copyright © 2017 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; Appropriate Use Criteria; Appropriateness Criteria; CT; MRI; cirrhosis; elastography; fibrosis; hepatocellular carcinoma; liver disease; ultrasound

Mesh:

Year:  2017        PMID: 28473066     DOI: 10.1016/j.jacr.2017.02.011

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  5 in total

1.  Sonographic evaluation of the portal vein diameter in patients with chronic liver disease in northeastern Nigeria.

Authors:  Geofery Luntsi; Musa Abubakar Muhammad; Yakubu Bababa Shirama; Mohammed Lawal Mohammed; Aliyu Suleiman; Kalu Ochie
Journal:  Ultrasound       Date:  2020-07-29

Review 2.  Magnetic resonance elastography of the liver: everything you need to know to get started.

Authors:  Kay M Pepin; Christopher L Welle; Flavius F Guglielmo; Jonathan R Dillman; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2021-11-01

Review 3.  REVIEW: MR elastography of brain tumors.

Authors:  Adomas Bunevicius; Katharina Schregel; Ralph Sinkus; Alexandra Golby; Samuel Patz
Journal:  Neuroimage Clin       Date:  2019-11-23       Impact factor: 4.881

4.  Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy.

Authors:  Chance S Friesen; Chelsea Hosey-Cojocari; Sherwin S Chan; Iván L Csanaky; Jonathan B Wagner; Brooke R Sweeney; Alec Friesen; Jason D Fraser; Valentina Shakhnovich
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-13       Impact factor: 5.555

5.  Diagnostic performance of tomoelastography of the liver and spleen for staging hepatic fibrosis.

Authors:  Rolf Reiter; Heiko Tzschätzsch; Florian Schwahofer; Matthias Haas; Christian Bayerl; Marion Muche; Dieter Klatt; Shreyan Majumdar; Meltem Uyanik; Bernd Hamm; Jürgen Braun; Ingolf Sack; Patrick Asbach
Journal:  Eur Radiol       Date:  2019-11-11       Impact factor: 5.315

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.